By: IPP Bureau
Last updated : March 20, 2026 1:48 pm
Glenmark's Milnacipran Hydrochloride Tablets, 12.5 mg, 25 mg, 50 mg, and 100 mg is the authorized generic to Savella Tablets, 12.5 mg, 25 mg, 50 mg, and 100 mg
Glenmark Pharmaceuticals Inc., USA (Glenmark) announces the launch of Milnacipran Hydrochloride Tablets, 12.5 mg, 25 mg, 50 mg, and 100 mg. Glenmark's Milnacipran Hydrochloride Tablets, 12.5 mg, 25 mg, 50 mg, and 100 mg is the authorized generic to Savella Tablets, 12.5 mg, 25 mg, 50 mg, and 100 mg.
According to IQVIATM sales data for the 12-month period ending January 2026, the Savella Tablets, 12.5 mg, 25 mg, 50 mg, and 100 mg market2 achieved annual sales of approximately $102.9 million.
Commenting on the launch, Marc Kikuchi, President & Business Head, North America said, "We are excited to announce the launch of Milnacipran Hydrochloride Tablets, 12.5 mg, 25 mg, 50 mg, and 100 mg, the authorized generic to Savella® Tablets. This launch further strengthens our commitment to bring to market quality and affordable alternatives for patients."